No Data
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): The overseas business accounts for a relatively small proportion of the company's overall business.
Gelonghui reported on February 11 that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated on the investor interaction platform that overseas Business accounts for a small proportion of the company's overall Business.
China Resources 39:2024 Annual Results Report
China Resources Pharmaceutical's Shenzhen Listed Subsidiary Records 18% Higher Net Attributable Profit for 2024
Express News | China Resources Sanjiu Medical & Pharmaceutical Prelim 2024 Net Profit up 18.1%
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) performance quick report: In 2024, the net income attributable to shareholders is 3.369 billion yuan, an increase of 18.10% year-on-year.
On February 10, the company China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) announced its performance report for the 2024 fiscal year. In 2024, the company achieved a total operating revenue of 27.617 billion yuan, an increase of 11.63% year-on-year; achieved a total profit of 4.596 billion yuan, an increase of 22.40% year-on-year; achieved a net income of 3.369 billion yuan attributable to shareholders of the listed company, an increase of 18.10% year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 3.115 billion yuan, an increase of 14.91% year-on-year; and the EPS was 2.63 yuan.
Express News | Tasly Pharmaceutical Says China Resources Sanjiu Medical Gets State Asset Regulator's Approval for Buying Stake in Company
China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Investors Will Be Pleased With Their Strong 123% Return Over the Last Three Years
